PDF(Pubmed)
Abstract：
BACKGROUND: Breast angiosarcoma is a rare malignancy of endovascular origin, accounting for less than 1% of all mammary cancers. Our aim was to explore clinicopathological features and the factors associated with prognosis.
METHODS: We extracted information from the Surveillance, Epidemiology, and End Results Program (SEER) for all patients with breast angiosarcoma between 2004 and 2015. Chi-square analysis was used to compare the clinicopathological features in all patients. Overall survival (OS) was assessed using the Kaplan and Meier method. Univariate and multivariate analyses were performed to evaluate the factors associated with prognosis.
RESULTS: A total of 247 patients were included in the analyses. The median OS of patients with primary breast angiosarcoma (PBSA) and secondary breast angiosarcoma (SBAB) was 38 months and 42 months, respectively. The 1-, 3- and 5-year OS with PBSA was 80%, 39%, and 25%, respectively, and the 1-, 3- and 5-year OS with SBAB was 80%, 42%, and 34%, respectively. Multivariate analysis revealed that tumor size (p = 0.001), tumor grade (p < 0.001), tumor extension (p = 0.015), and tumor spread (p < 0.001) were statistically significant factors for OS. Partial mastectomy with radiation (HR = 0.160, 95% CI, 0.036-0.719, p = 0.016), partial mastectomy with chemotherapy (HR = 0.105, 95% CI, 0.011-1.015, p = 0.052), and partial mastectomy (HR = 0.125, 95% CI, 0.028-0.583, p = 0.007) were related to significantly better OS outcomes in primary angiosarcoma.
CONCLUSIONS: Primary breast angiosarcoma has a better clinical phenotype than secondary breast angiosarcoma. Although overall survival was not statistically significant, primary breast angiosarcoma was better than secondary breast angiosarcoma with systemic therapy. Depending on the outcome of survival, partial mastectomy is effective in treating primary breast angiosarcoma.
METHODS: We extracted information from the Surveillance, Epidemiology, and End Results Program (SEER) for all patients with breast angiosarcoma between 2004 and 2015. Chi-square analysis was used to compare the clinicopathological features in all patients. Overall survival (OS) was assessed using the Kaplan and Meier method. Univariate and multivariate analyses were performed to evaluate the factors associated with prognosis.
RESULTS: A total of 247 patients were included in the analyses. The median OS of patients with primary breast angiosarcoma (PBSA) and secondary breast angiosarcoma (SBAB) was 38 months and 42 months, respectively. The 1-, 3- and 5-year OS with PBSA was 80%, 39%, and 25%, respectively, and the 1-, 3- and 5-year OS with SBAB was 80%, 42%, and 34%, respectively. Multivariate analysis revealed that tumor size (p = 0.001), tumor grade (p < 0.001), tumor extension (p = 0.015), and tumor spread (p < 0.001) were statistically significant factors for OS. Partial mastectomy with radiation (HR = 0.160, 95% CI, 0.036-0.719, p = 0.016), partial mastectomy with chemotherapy (HR = 0.105, 95% CI, 0.011-1.015, p = 0.052), and partial mastectomy (HR = 0.125, 95% CI, 0.028-0.583, p = 0.007) were related to significantly better OS outcomes in primary angiosarcoma.
CONCLUSIONS: Primary breast angiosarcoma has a better clinical phenotype than secondary breast angiosarcoma. Although overall survival was not statistically significant, primary breast angiosarcoma was better than secondary breast angiosarcoma with systemic therapy. Depending on the outcome of survival, partial mastectomy is effective in treating primary breast angiosarcoma.
摘要：
背景：乳腺血管肉瘤是一种罕见的血管内恶性肿瘤，占所有乳腺癌的不到1%。我们的目的是探讨临床病理特征和与预后相关的因素。
方法：我们从监测中提取信息，流行病学,以及2004年至2015年期间所有乳腺血管肉瘤患者的最终结果计划（SEER）。用卡方分析比较所有患者的临床病理特征。使用Kaplan和Meier方法评估总生存期(OS)。进行单因素和多因素分析以评估与预后相关的因素。
结果：共247例患者纳入分析。原发性乳腺血管肉瘤(PBSA)和继发性乳腺血管肉瘤(SBAB)患者的中位OS分别为38个月和42个月,分别。1-,PBSA的3年和5年OS为80%，39%,25%,分别,和1-，SBAB的3年和5年OS为80%，42%,34%,分别。多因素分析显示肿瘤大小(p=0.001)，肿瘤分级（p<0.001），肿瘤扩展（p=0.015），和肿瘤扩散(p<0.001)是OS的统计学显著因素。乳房部分切除术伴放疗(HR=0.160,95%CI,0.036-0.719,p=0.016),乳房部分切除术加化疗(HR=0.105,95%CI,0.011-1.015,p=0.052),和部分乳房切除术（HR=0.125，95％CI，0.028-0.583，p=0.007）与原发性血管肉瘤的OS结局显着改善相关。
结论：原发性乳腺血管肉瘤比继发性乳腺血管肉瘤具有更好的临床表型。尽管总生存率没有统计学意义，在全身治疗下,原发性乳腺血管肉瘤优于继发性乳腺血管肉瘤.根据生存的结果，乳房部分切除术可有效治疗原发性乳腺血管肉瘤。
方法：我们从监测中提取信息，流行病学,以及2004年至2015年期间所有乳腺血管肉瘤患者的最终结果计划（SEER）。用卡方分析比较所有患者的临床病理特征。使用Kaplan和Meier方法评估总生存期(OS)。进行单因素和多因素分析以评估与预后相关的因素。
结果：共247例患者纳入分析。原发性乳腺血管肉瘤(PBSA)和继发性乳腺血管肉瘤(SBAB)患者的中位OS分别为38个月和42个月,分别。1-,PBSA的3年和5年OS为80%，39%,25%,分别,和1-，SBAB的3年和5年OS为80%，42%,34%,分别。多因素分析显示肿瘤大小(p=0.001)，肿瘤分级（p<0.001），肿瘤扩展（p=0.015），和肿瘤扩散(p<0.001)是OS的统计学显著因素。乳房部分切除术伴放疗(HR=0.160,95%CI,0.036-0.719,p=0.016),乳房部分切除术加化疗(HR=0.105,95%CI,0.011-1.015,p=0.052),和部分乳房切除术（HR=0.125，95％CI，0.028-0.583，p=0.007）与原发性血管肉瘤的OS结局显着改善相关。
结论：原发性乳腺血管肉瘤比继发性乳腺血管肉瘤具有更好的临床表型。尽管总生存率没有统计学意义，在全身治疗下,原发性乳腺血管肉瘤优于继发性乳腺血管肉瘤.根据生存的结果，乳房部分切除术可有效治疗原发性乳腺血管肉瘤。
